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ABSTRACT
Introduction: Health-related quality of life
(HRQoL) is an important part of the clinical
assessment and management of psoriasis. Few
studies have investigated the effects of
withdrawing treatment on the relationship
between HRQoL and objective clinical
manifestations of psoriasis. This post hoc
subanalysis of a clinical trial (REVEAL)
examined the relationship of HRQoL [assessed
with the Dermatology Life Quality Index
(DLQI)] and objective disease activity [assessed
with the Psoriasis Area and Severity Index
(PASI)] among patients before and after they
underwent protocol-mandated discontinuation
of psoriasis therapy.
Methods: Adult patients with moderate-to-
severe plaque psoriasis who received
adalimumab from baseline and had 75% or
greater improvement in the PASI score at weeks
16 and 33 were re-randomized to adalimumab
40 mg or placebo every other week from weeks
33 to 52. DLQI and PASI scores were compared
at baseline (week 0), early in treatment (week 4),
directly before randomized withdrawal (week
33), and up to 19 weeks after treatment
discontinuation (week 52; last observations
carried forward). Correlations between DLQI
total score and PASI score at week 4 and week 52
were modeled by linear regression.
Results: In the patients (N = 240) who
underwent protocol-mandated discontinuation
of psoriasis treatment after achieving PASI 75
response, mean PASI scores at week 52 were
lower (i.e., better) compared with week 4, yet
mean DLQI scores were higher (i.e., worse). An
approximately twofold disproportionately
greater degree of worsening of DLQI score
compared with the degree of worsening of
PASI was observed while patients underwent
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discontinuation of therapy (week 52) compared
with early in treatment (week 4). There was a
significant interaction (P\0.0001) between the
PASI–DLQI correlation and study period (week 4
or 52).
Conclusion: Discontinuing therapy in patients
who initially responded to treatment, as seen
in this analysis with adalimumab,
disproportionately worsened patient-reported
HRQoL relative to the worsening of PASI.
Keywords: Adalimumab; Dermatology; Life
Quality Index; Health-related quality of life;
Psoriasis Area and Severity Index; Treatment
discontinuation
INTRODUCTION
Psoriasis is a major inflammatory disease with
significant associated comorbidities, including
cardiovascular disease, inflammatory bowel
disease, metabolic syndrome, and psoriatic
arthritis [1]. Health-related quality of life
(HRQoL) is increasingly recognized as an
important element of the overall clinical
assessment of psoriasis rather than simply an
adjunct to objective measures of disease [2]. The
Dermatology Life Quality Index (DLQI) is a
short, self-administered, dermatology-specific
questionnaire that is the most commonly used
tool to evaluate HRQoL in psoriasis clinical
research [2, 3]. Objective clinical manifestations
of psoriasis are commonly assessed with the
Psoriasis Area and Severity Index (PASI), a
validated scale that has been demonstrated to
quantify clinical improvement in response to
treatment [4, 5].
Although it is difficult to correlate absolute
values of the PASI and DLQI, several studies
have explored the relationship between
reductions in the objective severity of psoriasis
as measured with the PASI and improvements
in HRQoL as measured with the DLQI [6]. In
secondary analyses of 1,469 patients with
moderate-to-severe plaque psoriasis from two
clinical trials of the tumor necrosis factor (TNF)
inhibitor adalimumab, a 90% or greater
improvement in the PASI (PASI 90 response)
was associated with a greater improvement in
the DLQI than that associated with a 75% or
greater improvement in the PASI (PASI 75
response) [7]. Further, a study of the TNF
inhibitor infliximab for severe plaque psoriasis
demonstrated that the percent change in the
PASI and the percent change in the DLQI for the
combined infliximab and placebo groups were
strongly correlated (Spearman’s correlation of
0.61) [8]. Additionally, patients who achieved a
PASI 75 response had a greater mean
improvement in the DLQI (81%) compared
with patients who achieved 50–75%
improvement in the PASI (60% improvement
in the DLQI). Katugampola et al. [9] examined
associations between the PASI and the DLQI in
multiple clinical trials of four biologics
(etanercept, infliximab, efalizumab, and
alefacept) and reported that improvement in
the DLQI paralleled improvement in the PASI
75 with treatment. Conversely, patients who
had responded to ustekinumab treatment (PASI
75 responders) and were re-randomized to
placebo during a withdrawal period exhibited
rapid worsening of DLQI scores in parallel with
loss of the PASI response; however, the
association between DLQI and PASI scores was
not formally analyzed [10]. To date, no studies
have compared the correlation between PASI
and DLQI scores during effective disease control
and after withdrawal of therapy.
In a double-blind, randomized, controlled
phase 3 trial (Randomized Controlled
EValuation of Adalimumab Every Other Week
Dosing in Moderate to Severe Psoriasis TriAL
[REVEAL]; Clinicaltrials.gov #NCT00237887),
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patients who underwent a protocol-mandated
discontinuation of treatment at week 33
experienced a loss of adequate response
[defined as a \50% reduction in PASI score
relative to baseline (week 0) and a C6-point
increase in the PASI score compared with week
33] at a significantly higher rate than patients
who were randomized to continue active
treatment (28% vs. 5%; P\0.001) [11]. We
hypothesized that patients who had achieved a
clinical response in REVEAL and whose
treatment was then discontinued would
experience a worsening of dermatology-
specific HRQoL out of proportion to the
worsening of the objective signs of disease.
METHODS
Study Design
This was a post hoc analysis of a phase 3,
multicenter, 52-week, double-blind, placebo-
controlled trial (REVEAL) performed at 81 sites
across the USA and Canada (Clinicaltrials.gov
#NCT00237887) [11]. The protocol was
approved by the institutional review board of
each participating medical center. The REVEAL
study consisted of three treatment periods
(Fig. 1). In period A (weeks 0–16), patients were
randomized 2:1 using an interactive voice
response system to receive double-blind
subcutaneous injections of adalimumab or
placebo. An initial dose of adalimumab (80 mg)
or placebo was administered at week 0, followed
by 40 mg adalimumab or placebo every other
week (eow) from weeks 1 to 15. Patients who
achieved PASI 75 at week 16 were eligible to enter
the open-label period (period B, weeks 16–33). To
maintain blinding at week 16, patients who had
received placebo during period A received two
injections of adalimumab (40 mg), while
patients who had received adalimumab were
given two injections of placebo. All patients
received adalimumab (40 mg eow) from weeks
17 to 31. Patients who achieved PASI 75
responses at week 33 were eligible to enter
period C (weeks 33–52). Patients originally
randomized to adalimumab in period A were
then re-randomized 1:1 to receive double-blind
adalimumab or placebo from weeks 33 to 52
(period C). Patients who received placebo in
period C are the focus of this analysis.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000. Informed consent was obtained from all
patients for being included in the study.
Patients
Males and females aged 18 years or older with a
clinical diagnosis of moderate-to-severe plaque
psoriasis (affected body surface area C10%) for
at least 6 months were eligible for the REVEAL
study [11]. PASI scores of 12 or greater and
Physician’s Global Assessment of at least
‘‘moderate’’ were required for eligibility. Key
exclusion criteria included previous exposure to
any systemic anti-TNF therapy and the inability
to discontinue phototherapy or topical or
systemic therapies. All patients provided
written informed consent.
Efficacy Assessments
The DLQI consists of four components:
symptoms and feelings (DLQIS); daily
activities (DLQID); leisure (DLQIL); and
personal relationships (DLQIP). DLQI total
scores may range from 0 to 30, with a higher
score indicating poorer HRQoL. A DLQI total
score of more than 5 indicates a moderate effect
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of psoriasis on patient HRQoL; a DLQI score of
more than 10 indicates a very large effect; and a
DLQI score of more than 20 indicates an
extremely large effect [12]. Thus, a DLQI total
score of more than 10 supports the need for a
more aggressive intervention. PASI scores may
range from 0 to 72, with higher scores
indicating greater disease severity. Post hoc
comparisons of DLQI and PASI scores were
evaluated at baseline, early in treatment (week
4), at the last point when all patients had at
least a PASI 75 response (week 33), and after
randomized treatment discontinuation (up to
19 weeks after discontinuation).
Statistical Analysis
Patients who received adalimumab during
period A, achieved PASI 75 responses at week
16 and week 33, and were subsequently re-
randomized to placebo during period C were
the focus of this subanalysis. Missing data were
imputed using the last observation carried
forward. The correlation between DLQI
component or total score and PASI score at
weeks 4 and 52 was analyzed by linear
regression using SAS version 9.1 (SAS Institute
Inc., Cary, NC, USA). No other statistical




Demographic and baseline disease activity
characteristics of patients (N = 240) in the
subanalysis population (Table 1) appeared
Fig. 1 REVEAL study design. Patients originally random-
ized to adalimumab in period A (weeks 0–16) who achieved
PASI 75 responses at week 16 (after double-blind treatment)
and week 33 [after open-label period B (weeks 16–33)] were
then re-randomized to double-blind adalimumab or placebo
in period C (weeks 33–52). This analysis examined the
cohort of 240 patients treated with placebo in period C.
*40 mg eow from week 1 after 80 mg at week 0; 40 mg eow
from week 17 after 80 mg at week 16. Adapted with
permission from Menter et al. [11]. DBPC double-bind,
placebo controlled, eow every other week, OLE open-label
extension, PASI Psoriasis Area and Severity Index, REVEAL
Randomized Controlled EValuation of Adalimumab Every
Other Week Dosing in Moderate to Severe Psoriasis TriAL
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generally similar to those of patients in the
overall study population [11]. The mean age of
patients was approximately 43 years; most
patients were male and nearly all were white.
Baseline disease characteristics were consistent
with moderate-to-severe psoriasis; the mean
DLQI score at baseline (11.6) was [10,
suggesting that, on average, psoriasis had a
very large effect on HRQoL.
PASI Response
The proportion of patients with PASI 75, PASI
90, or PASI 100 responses decreased after
discontinuation of therapy (Fig. 2). All patients
had PASI 75 responses at week 33, but most of
these patients lost PASI 75 response at week 52,
following discontinuation of treatment.
Similarly, the proportion of patients achieving
a PASI 90 response decreased from 71.7% at
week 33 to 20.3% at week 52, and the PASI 100
response rate decreased from 37.9% at week 33
to 8.4% at week 52. Thus, discontinuation of
therapy at week 33 resulted in recurrence of
psoriasis symptoms by week 52.
PASI vs. DLQI
Mean PASI and DLQI scores at baseline, week 4,
week 33, and week 52 are reported in Fig. 3.
Mean PASI scores decreased from baseline to
week 4 and continued to decline until week 33,
indicating improvement in psoriasis symptoms.
Mean PASI score increased from week 33 to
week 52, indicating recurrence of disease
symptoms upon discontinuation of treatment.
Mean DLQI scores followed a similar pattern.
However, although the mean PASI score at week
52 (6.7) remained lower than the PASI score at
week 4 (8.0), the mean DLQI score at week 52
(5.3) was higher than at week 4 (4.3). Therefore,
at the end of the study, PASI scores remained
lower (indicating an improvement) compared
with early treatment, whereas the mean DLQI
Table 1 Demographics and baseline clinical characteristics of patients re-randomized to placebo during period C
Double-blind period C (N5 240)
Age (mean ± SD), years 43.4 ± 13.2
Male, n (%) 179 (74.6)
White, n (%) 222 (92.5)
Weight (mean ± SD), kg 88.5 ± 19.2
PASI score (mean ± SD) 19.5 ± 7.8
BSA (mean ± SD), % 27.0 ± 16.8
VAS for plaque psoriasis and psoriatic arthritis (mean ± SD) 38.6 ± 30.0a
Psoriasis-related pruritus assessment (mean ± SD) 7.1 ± 2.3a
DLQI score (mean ± SD) 11.6 ± 6.8
Patients originally randomized to adalimumab in period A (weeks 0–16) who achieved PASI 75 responses at week 16 (after
double-blind treatment) and week 33 [after open-label period B (weeks 16–33)] were then re-randomized to double-blind
adalimumab or placebo in period C (weeks 33–52)
BSA body surface area affected by psoriasis, DLQI Dermatology Life Quality Index, PASI Psoriasis Area and Severity Index,
VAS visual analog scale
a n = 237
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score was worse at the end of the study
compared with a time point early in
treatment, suggesting a disproportionate
worsening of HRQoL relative to the severity of
psoriasis.
To examine the association between the PASI
and DLQI, the correlation between PASI scores
and DLQI scores was evaluated by linear
regression early in treatment (week 4) and
19 weeks after discontinuation of therapy
(week 52). For every unit increase in PASI
score, there was a disproportionately larger
increase (i.e., worsening) in DLQI total score at
week 52 compared with week 4 (Fig. 4). The
slope of the regression line for DLQI versus PASI
was 0.5094 at week 52 and 0.1978 at week 4,
indicating that each unit change in PASI was
associated with approximately twice as much
change in DLQI at week 52 compared with the
change at week 4. Linear regression modeling
showed a significant interaction (P\0.0001)
between study period (week 4 or week 52) and
the relationship of PASI to DLQI, indicating
that the correlation between PASI and DLQI was
different early in treatment (week 4) from the
correlation 19 weeks after discontinuation of
treatment (week 52). The disproportionate
worsening in DLQI scores was less apparent for
patients with PASI 75 responses. Patients who
experienced substantial worsening of disease
(e.g., \PASI 50) had the largest difference in
DLQI scores between week 4 and week 52
Fig. 2 Proportion of patients achieving PASI 75, PASI 90,
and PASI 100 responses over time in the ITT population
(LOCF). Patients who achieved PASI 75 responses with
adalimumab at week 33 and then discontinued treatment
(received placebo) until week 52 are presented. For week
52, only patients who had at least 1 post-week 33
assessment were included in the LOCF analysis. ITT
intent to treat, LOCF last observation carried forward,
PASI Psoriasis Area and Severity Index
Fig. 3 Mean PASI (a) and DLQI (b) scores in the ITT
population (LOCF). Adalimumab was discontinued at
week 33. PASI scale: 0–72. DLQI scale: 0–30. DLQI
Dermatology Life Quality Index, ITT intent to treat,
LOCF last observation carried forward, PASI Psoriasis Area
and Severity Index
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(Fig. 5). Changes in these patients made the
largest contribution to the mean worsening of
DLQI scores. Correlations of individual DLQI
component scores with PASI also differed before
and after discontinuation of therapy. The slope
of the regression line for DLQID versus PASI was
0.0413 at week 4 and 0.1153 at week 52; DLQIL
versus PASI was 0.0384 at week 4 and 0.0849 at
week 52; DLQIP versus PASI was 0.0281 at week
4 and 0.0578 at week 52; and DLQIS versus PASI
was 0.0644 at week 4 and 0.1704 at week 52.
Thus, the correlations of DLQIS and DLQID
with PASI exhibited the most striking
differences between a time point early in
treatment and after discontinuation.
DISCUSSION
Within 19 weeks after therapy was discontinued
per protocol in patients who had responded
well to treatment, PASI and DLQI scores showed
recurrence of psoriasis symptoms and increased
impairment of HRQoL. A post hoc analysis
demonstrated that DLQI total scores worsened
disproportionately relative to PASI scores, a
difference that reached statistical significance;
thus, HRQoL worsened disproportionately
relative to the objective signs of disease
recurrence. The patterns of correlations of
DLQI component scores with PASI scores
before and after treatment discontinuation
supported the results obtained for the DLQI
total score. Although the reason for the
asymmetry between PASI and DLQI cannot be
determined from the results of this analysis, we
hypothesize that it occurred because patients
were distressed by the recurrence of psoriasis
symptoms that had been effectively controlled.
Even mild disease recurrence may have had a
negative effect on DLQI scores, perhaps because
patients recalled the previous deleterious effects
of more severe disease activity on their HRQoL.
The psychological impact of psoriasis on
patients is well documented. Patients with
psoriasis have higher levels of anxiety and
depression than healthy controls and often
experience emotions of shame, worry, anger,
and annoyance [13–15]. Recently, Ghajarzadeh
et al. [16] reported significant correlations
between DLQI scores and Beck Depression
Fig. 4 Scatter plot for week 4 and week 52 DLQI vs. PASI
(LOCF; ITT population). DLQI Dermatology Life Qual-
ity Index, ITT intent to treat, LOCF last observation
carried forward, PASI Psoriasis Area and Severity Index
Fig. 5 Mean DLQI score by PASI response categories.
DLQI Dermatology Life Quality Index, PASI Psoriasis
Area and Severity Index
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Inventory (BDI) scores in patients with
psoriasis. Patients with psoriasis had BDI
scores indicative of mild-to-moderate
depression and DLQI scores demonstrating
impaired HRQoL.
The results of this exploratory analysis of
randomized withdrawal of adalimumab are
consistent with a substantial link between
treatment response and patient HRQoL; we
hypothesize that findings would be similar
with discontinuation of other treatments. The
results of the current study highlight the
importance of continuous therapy in
patients with psoriasis. Even temporary
discontinuations of treatment may be
inadvisable in patients who have achieved
disease control. Conversely, in the authors’
clinical experience, the erosion of HRQoL after
treatment interruption may be a primary factor
in influencing patients to reinitiate therapy. In
support of these considerations, a recent
systematic review concluded that continuous
therapy is preferred for maintenance of disease
control and HRQoL [17].
This study benefited from a double-blind
design that may have minimized bias by
masking assignment to continue adalimumab
or receive placebo; this was probably
particularly important for a subjective, patient-
reported outcome such as the DLQI. Additional
strengths were that the study was conducted at
a large number of centers and that many
patients were analyzed. Limitations of the
study are that it was a post hoc analysis and,
therefore, potentially subject to bias.
Additionally, the comparison of PASI and
DLQI scores was not evaluated beyond the
relatively short period of 19 weeks after
discontinuation of treatment. Finally, inherent
limitations of the DLQI and PASI have been
reported. Problems with the DLQI include
inadequate measurement of mild illness,
interpretability that has been rated only
‘‘acceptable,’’ and differential item functioning
by disease, age, and sex [3, 18]. Although the
PASI is the most thoroughly validated scale
for psoriasis and is used extensively in
clinical trials [4], it has been criticized for
having a nonlinear scale, poor sensitivity, and
lack of standardization for translation into
corresponding clinical severity categories [19].
PASI scores on the lower end of the range (PASI
\10) are less meaningful, so comparisons with
DLQI scores among patients with low PASI
scores may be more difficult. Furthermore,
consistency and reliability of the PASI are
influenced by the experience level of the
physician [20]. Due to these limitations, this
analysis must be considered exploratory and
hypothesis generating; a prospective study
would be needed to confirm the findings.
CONCLUSION
Discontinuing therapy, as observed in this
analysis with adalimumab, has several
negative effects in patients with psoriasis,
including a loss of objective response and a
disproportionately large negative impact on
HRQoL. Interruption of treatment will likely
result in an increase of psoriasis symptoms and
a disproportionate decrease in HRQoL.
ACKNOWLEDGMENTS
AbbVie Inc. funded this study and participated
in the study design, data collection, data
management, data analysis, and preparation of
the manuscript. All authors had full access to
the data and analyses; were involved in the
writing, review of, and decision to submit the
manuscript for publication; and vouch for the
accuracy and completeness of the data analyses
40 Dermatol Ther (Heidelb) (2014) 4:33–42
and results presented. The data within this
manuscript were previously presented at the
70th Annual Meeting of the American Academy
of Dermatology in San Diego, CA, USA, March
16–20, 2012. Medical writing support was
provided by Amanda Sheldon, PhD, of
Complete Publication Solutions, LLC; this
support was funded by AbbVie Inc.
Conflict of interest. Yves Poulin has
participated as an investigator, speaker, and as
a member of advisory boards for and has
received grant funding and honoraria from
AbbVie Inc., Amgen, and Centocor/Janssen-
Ortho/Johnson & Johnson. Yves Poulin has
also received grant funding as an investigator
for Celgene, Eli Lilly, LEO Pharma, Merck,
Novartis, and Pfizer. Pranav Sheth has served
as a speaker for AbbVie and LEO Pharma, and
has served as principal investigator on clinical
trials supported by AbbVie; funding for these
studies went directly to his institution. Pranav
Sheth has also participated as a member on
advisory boards for AbbVie and Amgen. Yihua
Gu and Henrique D. Teixeira are employees of
AbbVie and may hold AbbVie stock or stock
options.
Compliance with ethics guidelines. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000. Informed consent was obtained from all
patients for being included in the study.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Mrowietz U, Elder JT, Barker J. The importance of
disease associations and concomitant therapy for
the long-term management of psoriasis patients.
Arch Dermatol Res. 2006;298:309–19.
2. Basra MK, Hussain S. Application of the
Dermatology Life Quality Index in clinical trials of
biologics for psoriasis. Chin J Integr Med. 2012;18:
179–85.
3. Bronsard V, Paul C, Prey S, et al. What are the best
outcome measures for assessing quality of life in
plaque type psoriasis? A systematic review of the
literature. J Eur Acad Dermatol Venereol.
2010;24(Suppl 2):17–22.
4. Puzenat E, Bronsard V, Prey S, et al. What are the
best outcome measures for assessing plaque
psoriasis severity? A systematic review of the
literature. J Eur Acad Dermatol Venereol. 2010;24
(Suppl 2):10–6.
5. Robinson A, Kardos M, Kimball AB. Physician
Global Assessment (PGA) and Psoriasis Area and
Severity Index (PASI): why do both? A systematic
analysis of randomized controlled trials of biologic
agents for moderate to severe plaque psoriasis. J Am
Acad Dermatol. 2012;66:369–75.
6. Reich K, Griffiths CE. The relationship between
quality of life and skin clearance in moderate-to-
severe psoriasis: lessons learnt from clinical trials
with infliximab. Arch Dermatol Res. 2008;300:
537–44.
7. Revicki DA, Willian MK, Menter A, Saurat JH,
Harnam N, Kaul M. Relationship between clinical
response to therapy and health-related quality of
life outcomes in patients with moderate to severe
plaque psoriasis. Dermatology. 2008;216:260–70.
8. Feldman SR, Gordon KB, Bala M, et al. Infliximab
treatment results in significant improvement in the
quality of life of patients with severe psoriasis: a
double-blind placebo-controlled trial. Br J
Dermatol. 2005;152:954–60.
9. Katugampola RP, Lewis VJ, Finlay AY. The
Dermatology Life Quality Index: assessing the
efficacy of biological therapies for psoriasis. Br J
Dermatol. 2007;156:945–50.
Dermatol Ther (Heidelb) (2014) 4:33–42 41
10. Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-
term efficacy of ustekinumab in patients with
moderate-to-severe psoriasis: results from the
PHOENIX 1 trial through up to 3 years. Br J
Dermatol. 2012;166:861–72.
11. Menter A, Tyring SK, Gordon K, et al. Adalimumab
therapy for moderate to severe psoriasis: a
randomized, controlled phase III trial. J Am Acad
Dermatol. 2008;58:106–15.
12. Hongbo Y, Thomas CL, Harrison MA, Salek MS,
Finlay AY. Translating the science of quality of life
into practice: what do Dermatology Life Quality
Index scores mean? J Invest Dermatol. 2005;125:
659–64.
13. Golpour M, Hosseini SH, Khademloo M, et al.
Depression and anxiety disorders among patients
with psoriasis: a hospital-based case–control study.
Dermatol Res Pract. 2012;2012:381905.
14. Palijan TZ, Kovacevic D, Koic E, Ruzic K, Dervinja F.
The impact of psoriasis on the quality of life and
psychological characteristics of persons suffering
from psoriasis. Coll Antropol. 2011;35(Suppl 2):81–5.
15. Sampogna F, Tabolli S, Abeni D. Living with
psoriasis: prevalence of shame, anger, worry, and
problems in daily activities and social life. Acta
Derm Venereol. 2012;92:299–303.
16. Ghajarzadeh M, Ghiasi M, Kheirkhah S.
Associations between skin diseases and quality of
life: a comparison of psoriasis, vitiligo, and alopecia
areata. Acta Med Iran. 2012;50:511–5.
17. Brezinski EA, Armstrong AW. Off-label biologic
regimens in psoriasis: a systematic review of
efficacy and safety of dose escalation, reduction,
and interrupted biologic therapy. PLoS ONE.
2012;7:e33486.
18. Twiss J, Meads DM, Preston EP, Crawford SR,
McKenna SP. Can we rely on the Dermatology
Life Quality Index as a measure of the impact of
psoriasis or atopic dermatitis? J Invest Dermatol.
2012;132:76–84.
19. Berth-Jones J, Grotzinger K, Rainville C, et al. A
study examining inter- and intrarater reliability of
three scales for measuring severity of psoriasis:
Psoriasis Area and Severity Index, Physician’s
Global Assessment and Lattice System Physician’s
Global Assessment. Br J Dermatol. 2006;155:
707–13.
20. Langley RG, Ellis CN. Evaluating psoriasis with
Psoriasis Area and Severity Index, Psoriasis Global
Assessment, and Lattice System Physician’s Global
Assessment. J Am Acad Dermatol. 2004;51:563–9.
42 Dermatol Ther (Heidelb) (2014) 4:33–42
